26
Participants
Start Date
January 31, 2018
Primary Completion Date
December 31, 2020
Study Completion Date
June 30, 2024
Laboratory Biomarker Analysis
Correlative studies
Pepinemab
Given IV
Pharmacological Study
Correlative studies
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Children's Hospital of The King's Daughters, Norfolk
Children's Healthcare of Atlanta - Egleston, Atlanta
Children's Hospital of Alabama, Birmingham
Saint Jude Children's Research Hospital, Memphis
Cincinnati Children's Hospital Medical Center, Cincinnati
Riley Hospital for Children, Indianapolis
C S Mott Children's Hospital, Ann Arbor
University of Minnesota/Masonic Cancer Center, Minneapolis
Lurie Children's Hospital-Chicago, Chicago
Washington University School of Medicine, St Louis
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
University of Texas Health Science Center at San Antonio, San Antonio
Children's Hospital Colorado, Aurora
Children's Hospital Los Angeles, Los Angeles
Children's Hospital of Orange County, Orange
UCSF Medical Center-Mission Bay, San Francisco
Seattle Children's Hospital, Seattle
Yale University, New Haven
Dana-Farber Cancer Institute, Boston
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK